Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Bernie Sanders calls for RFK Jr. to resign...
Top Senate Republican ready to go nuclear, ‘roll...
Altech Batteries LtdCERENERGY Battery 46.7M Euro German Grant...
Altech – CERENERGY Battery 46.7M Euro German Grant...
Locksley Resources LimitedStrengthens Leadership to Accelerate Growth Strategy
Heliostar Presents Second Quarter 2025 Financial Results
Apollo to Proceed with 5-for-1 Share Consolidation
Rhode Island’s ‘Taylor Swift Tax’ on vacation homes...
Former FBI Director Robert Mueller has Parkinson’s disease:...
Earthwise Advertising & Investor Awareness Campaign
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

by admin July 22, 2025
July 22, 2025
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

 

Radiopharm Theranostics (ASX:RAD,OTC:RDPTF, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company’s Scientific Advisory Board (SAB).

 

Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine.

 

Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology.

 

Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI).

 

Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy.

 

‘Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,’ said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. ‘We’re very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.’

 

  About Radiopharm Theranostics  

 

 Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

 

  Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.  

 

  For more information:  

 

  Investors:  
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

 

Anne Marie Fields
Precision AQ
(Formerly Stern IR)
E: annemarie.fields@precisionaq.com

 

  Media:  
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

 

  Follow Radiopharm Theranostics:  

 

Website – https://radiopharmtheranostics.com/  
Twitter – https://twitter.com/TeamRadiopharm  
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/  
InvestorHub – https://investorhub.radiopharmtheranostics.com/

 

   

 

 

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

previous post
Orange juice importer says Brazil tariffs will squeeze American consumers
next post
Nuvau’s Gold-Focused Exploration Program Underway at Matagami

You may also like

Group Eleven Announces C$5M Bought Deal Private Placement

July 22, 2025

Nuvau Minerals Inc. Changes Financial Year-End

March 1, 2025

Binding Commitments Received for A$1.0 Million under Convertible...

April 28, 2025

Copper Price Update: Q1 2025 in Review

April 14, 2025

Gold Reaches New Price Record, Then Pulls Back;...

October 26, 2024

5 Top Weekly TSXV Stocks: Gold Stocks Lead...

August 12, 2024

Alta Mesa Passes Key Milestone in Uranium Production...

October 25, 2024

Heritage Provides Exploration Update on New Millennium Prospect...

February 27, 2025

Brunswick Continues to Intersect Lithium Mineralization on Globex’s...

April 26, 2025

Altech Batteries Limited (ASX: ATC) – Reinstatement to...

August 7, 2024

Recent Posts

  • Bernie Sanders calls for RFK Jr. to resign as HHS secretary over vaccine policies: ‘Rally the American people’
  • Top Senate Republican ready to go nuclear, ‘roll over’ Democrats with rule change to confirm Trump nominees
  • Altech Batteries LtdCERENERGY Battery 46.7M Euro German Grant Approval
  • Altech – CERENERGY Battery 46.7M Euro German Grant Approval
  • Locksley Resources LimitedStrengthens Leadership to Accelerate Growth Strategy

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (903)
    • Investing (2,877)
    • Politics (3,527)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.